title: Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.
abstract: Some patients are unable to achieve and maintain an undetectable plasma HIV-1 RNA level with combination antiretroviral therapy (ART) and are therefore maintained on a partially suppressive regimen. To determine the immune consequences of continuing ART despite persistent viremia, we randomized 47 ART-treated individuals with low to moderate plasma HIV-1 RNA levels (200-9999 copies/ml) to either an immediate switch in therapy or a delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml). After 48 weeks of follow-up, naive and memory CD4+ T cell percents were comparable in the two groups. The proportion of subjects with a lymphocyte proliferative response to Candida, Mycobacterium avium-intracellulare complex, or HIV-gag was also not significantly different at week 48. Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters.
authors.affiliation: Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S. Paulina Street, Chicago, IL 60612, USA. allan_s_tenorio@rush.edu
authors.forename: Allan R
authors.initials: AR
authors.lastname: Tenorio
authors.forename: Hongyu
authors.initials: H
authors.lastname: Jiang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zheng
authors.forename: Barbara
authors.initials: B
authors.lastname: Bastow
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: John A
authors.initials: JA
authors.lastname: Bartlett
authors.forename: Steven G
authors.initials: SG
authors.lastname: Deeks
authors.forename: Alan L
authors.initials: AL
authors.lastname: Landay
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Riddler
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002175:Candida / Q000276:immunology; D049109:Cell Proliferation; D024882:Drug Resistance, Viral; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D015269:Mycobacterium avium Complex / Q000276:immunology; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D012367:RNA, Viral